Context Therapeutics and The Menarini Group Announce Clinical ...
- Written by LATEST ASIANET NEWS RELEASES
- Published in Asia Net
PHILADELPHIA and FLORENCE, Italy, August 2, 2022 /PRNewswire-AsiaNet/ -- Preclinical data support the potential of ONA-XR plus estrogen receptor degraders in endocrine resistant disease modelsContext to initiate Phase 1b/2 clinical trial in Q4 2022Context Therapeutics Inc. ("Context" or the "Company") (Nasdaq: ...
Authors: LATEST ASIANET NEWS RELEASES